Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

CNTB vs ANRO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CNTB Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 5–4 Matrix Metrics)

CNTB Overall Winner 6-Pillar Tally: CNTB 4 – 1 ANRO (1 Tie) Matrix Metrics: CNTB 5 – 4 ANRO

As of Nov 17, 2026, Connect Biopharma Holdings Limited (CNTB) is the stronger overall head-to-head candidate over Alto Neuroscience Inc. (ANRO) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). CNTB carries a Unified Composite Score of 41.0/100 (SELL) at $0.59 (0.8x Forward P/E, -2384.5% operating margin), whereas ANRO carries 34.3/100 (SELL) at $25.12 (N/M Forward P/E, 0.0% operating margin).

  • Defensive Composite Rating Caution: Although CNTB compares more favorably head-to-head, both CNTB (41.0/100 SELL) and ANRO (34.3/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: CNTB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.6); meanwhile ANRO is in a Breakdown options structure phase (RSI 48.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CNTB vs ANRO
CNTB NASDAQ Head-to-Head Winner
Connect Biopharma Holdings Limited Ordinary Shares
Pharmaceutical Preparations
$0.59
-7.94% 1D
Market Cap $42.6M
TTM Revenue $3.0M
Forward P/E 0.8x
Beta / 30D Vol 0.92β · 68% Vol
Unified Composite Score
41.0 / 100 SELL
Tech 25.0 Fund 48.0 Flow 66.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -38.7%), weak momentum, RSI 26
RSI-14: 25.6 · SMA20: $0.75 · SMA50: $0.99
ANRO NYSE
Alto Neuroscience Inc.
Pharmaceutical Preparations
$25.12
-7.37% 1D
Market Cap $1.2B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.03β · 94% Vol
Unified Composite Score
34.3 / 100 SELL
Tech 15.0 Fund 38.0 Flow 64.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 48
RSI-14: 48.0 · SMA20: $24.87 · SMA50: $25.98

6-Pillar Scorecard Institutional Category Breakdown (CNTB 4 – 1 ANRO)

Columns: Metric · CNTB · ANRO
1. Valuation Multiples CNTB
Forward P/E 0.8x N/M
Trailing P/E 0.8x N/M
PEG Ratio N/M N/M
EV / Revenue 5.5x N/M
2. Growth & Scale CNTB
Revenue Growth (YoY) +5666.7% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $3.0M N/A
Market Cap $42.6M $1.2B
3. Profitability & Quality ANRO
Gross Margin 100.0% N/A
Operating Margin -2384.5% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -140.5% -46.7%
4. Balance Sheet & Cash Flow CNTB
Cash Generation (TTM) -$61M -$80M
Cash Flow Margin N/A N/A
Net Cash / Leverage $26M Net Cash $301M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CNTB
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 397.3% (100th %ile) 79.4% (8th %ile)
Put/Call OI Skew N/A 0.04x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CNTB (5) vs ANRO (4)
Institutional Metric CNTB ANRO Criterion Row Edge
Market Capitalization
Scale
$42.6M $1.2B Larger Scale ANRO
Trailing P/E Ratio
Valuation
0.8x N/M Lower Multiple CNTB
Forward P/E Ratio
Valuation
0.8x N/M Lower Multiple CNTB
Revenue Growth (YoY)
Growth
+5666.7% +0.0% Higher Growth CNTB
Operating Margin (TTM)
Profitability
-2384.5% 0.0% Higher Margin ANRO
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-140.5% -46.7% Higher ROE ANRO
52-Week Range Position
Momentum
1% ($1–$4) 54% ($11–$37) Stronger Trend ANRO
Beta / 30D Volatility
Risk Regime
0.92β · 68% Vol 2.03β · 94% Vol Lower Realized Risk CNTB
Unified Institutional Score
Composite Signal
41.0 / 100 (SELL) 34.3 / 100 (SELL) Higher Composite CNTB
Trailing 12M Revenue (USD)
Operating Scale
$3.0M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 5.5x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$61M ($26M Net Cash) -$80M ($301M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ANRO +44.3 pp
CNTB: -34.22% · ANRO: +10.08%
3M Horizon ANRO +47.94 pp
CNTB: -75.94% · ANRO: -28.0%
6M Horizon ANRO +95.81 pp
CNTB: -72.97% · ANRO: +22.84%
1Y Horizon ANRO +179.51 pp
CNTB: -72.08% · ANRO: +107.43%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CNTB vs ANRO. Trailing 12-month operating profitability (CNTB -2384.5% vs ANRO 0.0%) and valuation multiples (CNTB 0.8x vs ANRO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CNTB ADR TTM Benchmark FX-Normalized USD
TTM Revenue$3.0M
Gross Margin100.0%
Op. Margin-2384.5%
ROE / Fwd P/E-140.5% · 0.8x
ANRO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-46.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CNTB UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 397.3%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact CNTB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ANRO BREAKDOWN
58d in phase · OBV ACCUMULATION
Current IV 79.4%
IV Percentile 8th %ile
Put/Call OI Skew 0.04x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact ANRO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CNTB Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $42.6M market capitalization and -2384.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ANRO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.2B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CNTB vs ANRO Key Questions & Quantitative Answers

As of Nov 17, 2026, Connect Biopharma Holdings Limited (CNTB) is the stronger overall head-to-head candidate over Alto Neuroscience Inc. (ANRO) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). CNTB carries a Unified Composite Score of 41.0/100 (SELL) at $0.59 (0.8x Forward P/E, -2384.5% operating margin), whereas ANRO carries 34.3/100 (SELL) at $25.12 (N/M Forward P/E, 0.0% operating margin). Defensive Composite Rating Caution: Although CNTB compares more favorably head-to-head, both CNTB (41.0/100 SELL) and ANRO (34.3/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: CNTB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.6); meanwhile ANRO is in a Breakdown options structure phase (RSI 48.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CNTB leads the Growth & Scale pillar: CNTB posts +5666.7% YoY revenue growth and +0.0% YoY earnings growth on $3.0M TTM revenue (100.0% gross margin, -2384.5% operating margin), compared with ANRO at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, CNTB generates $3.0M in USD-normalized revenue versus N/A for ANRO. In operating R&D and SG&A reinvestment, CNTB deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ANRO.

CNTB screens cheaper on headline valuation multiples. CNTB trades at 0.8x Forward P/E, 0.8x Trailing P/E, N/M PEG, and 5.5x EV/Revenue (unreported FCF margin), whereas ANRO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CNTB (-140.5% ROE) versus ANRO (-46.7% ROE) capital efficiency.

In options market volatility and institutional positioning, CNTB carries 397.3% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.92β · 68% Vol realized risk). By comparison, ANRO carries 79.4% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.04x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (2.03β · 94% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.